Obez Hastalarda Olası İlaç-İlaç Etkileşimlerinin Değerlendirilmesi
Amaç: Polifarmasi, ilaç-ilaç etkileşimlerine bağlı yaşamı tehdit eden yan etkilere neden olabilmektedir. Çoklu ilaç kullanımını gerektiren
birçok ko-morbid hastalığı olduğu bilinen obez hastalarda polifarmasiye bağlı ilaç-ilaç etkileşimlerini gözlemlemek muhtemeldir. Bu
çalışmanın amacı, obez hastalarda olası ilaç-ilaç etkileşimlerinin sıklığını ve şiddetini belirlemektir.
Gereç ve Yöntemler: Bu kesitsel çalışmada, 1 Nisan 2016- 1 Temmuz 2017 tarihleri arasında üçüncü basamak bir hastanenin obezite
polikliniğine başvuran hastaların reçete verilerini analiz edildi. İlaç-ilaç etkileşimlerinin şiddeti, Lexi-comp® ilaç etkileşimi veri tabanı
kullanılarak yorumlandı. Hastaların demografik özellikleri [cinsiyet (erkek/kadın), yaş kategorileri (18-44, 45-64 ve ≥65 yaş),VKİ’leri
(30-34,9, 35-39,9 ve ≥40 kg/m2)], eşlik eden hastalıkları ve ilaç sayısına göre ilaç ilaç etkileşimi varlığının karşılaştırılması için ki-kare
testi uygulandı. p <0,05 değeri istatistiksel olarak anlamlı kabul edildi.
Bulgular: Değerlendirilen 476 hasta verisinde, toplam 781 ilaç reçete edildi. İki veya daha fazla ilaç reçete edilen 190 hasta arasında, 35
(%18,4) hastada bir veya daha fazla olası ilaç-ilaç etkileşimi vardı. 48 (%70,6) C, 12 (%17,6) B, 7 (%10,3) D ve 1 (%1,5) X risk kategorisi
ilaç-ilaç etkileşimi tespit edildi. En sık olası ilaç-ilaç etkileşimi metformin ve nonsteroidal antiinflamatuvar ilaçlar arasındaydı (%7,4).
Olası ilaç-ilaç etkileşimlerinin varlığı, reçete edilen ilaçların sayısı ile anlamlı düzeyde ilişkiliydi (p<0,001).
Sonuç: Obezite polikliniğindeki olası ilaç-ilaç etkileşimlerinin oranı nispeten düşüktü. Bununla birlikte, ilaç-ilaç etkileşimlerini en aza
indirmek için, hekimlerin obezite polikliniğinde sık reçete edilen ilaçlar arasındaki etkileşimlerin farkında olması ve ilaçların güvenli
kullanımı için hastaları izlemesi hayati önem taşımaktadır.
Assessment of Potential Drug-Drug Interactions in Obese Patients
Aim: Polypharmacy may cause life-threatening adverse effects due to drug-drug interactions (DDIs). It is possible to observe DDIs due
to polypharmacy in obese patients who is known to have many co-morbid diseases that necessitates multiple drug use. The aim of the
present study is to determine the frequency and severity of potential DDIs (pDDIs) in obese patients.
Material and Methods: This cross-sectional study analyzed the patient charts that admitted to obesity outpatient clinic of tertiary care
hospital from April 1, 2016 to July 1, 2017. The severity of DDIs was interpreted using the Lexi-comp® drug interaction database. A chisquare
test was performed for the comparison of the presence of DDIs based on patients’ demographic characteristics [gender (male/
female), age categories (18-44, 45-64 and ≥65 years) and BMI (30-34.9, 35-39.9 and ≥40 kg/m2)], co-morbid clinical conditions and
number of drugs. The comparisons were considered as statistically significant at p< 0.05.
Results: Out of 476 patient data evaluated, a total of 781 drugs were prescribed. Among 190 patients who were prescribed two or more
drugs, 35 (18.4%) patients had one or more pDDIs. We determined 48 (70.6%) C, 12 (17.6%) B, 7 (10.3%) D and 1 (1.5%) X risk category
interactions. The most common pDDIs were between metformin and nonsteroidal anti-inflammatory drugs (7.4%). The presence of
pDDIs was significantly associated with the number of prescribed drugs (p<0.001).
Conclusion: The pDDIs in obesity outpatient clinic were relatively low. Nevertheless, in order to minimize DDIs, it is vital for physicians
to be aware of the interactions between the frequently prescribed drugs in obesity outpatient clinic and monitor patients for the safe use
of drugs.
___
- 1. Nusair MB, Al-Azzam SI, Arabyat RM, Amawi HA, Alzoubi
KH, Rabah AA. The prevalence and severity of potential
drug-drug interactions among adult polypharmacy patients
at outpatient clinics in Jordan. Saudi Pharmaceutical Journal
2020; 28: 155–60.
- 2. İdrizoğlu MG, Küçükibrahimoğlu E, Karaalp A, Sarikaya O,
Demirkapu M, Onat F, et al. Potential drug–drug interactions
in a medical intensive care unit of a university hospital. Turk J
Med Sci 2016; 46: 812-9.
- 3. Morales-RõÂos O, Jasso-GutieÂrrez L, Reyes-LoÂpez A,
Garduño-Espinosa J, Muñoz-HernaÂndez O. Potential drugdrug
interactions and their risk factors in pediatric patients
admitted to the emergency department of a tertiary care
hospital in Mexico. PLoS ONE 2018; 13(1): e0190882.
- 4. De Palencia Espinosa MAF, Carrasco MSD, Soler JLF, Merino
GR, De la Rubia Nieto MA, Miro AE. Pharmacoepidemiological
study of drug-drug interactions in onco-hematological
pediatric patients. Int J Clin Pharm. 2014; 36:1160-1169.
- 5. Al-Ramahi R, Raddad AR, Rashed AO, Bsharat A, Abu-
Ghazaleh D, Yasin E, Shehab O. Evaluation of potential drugdrug
interactions among Palestinian hemodialysis patients.
MC Nephrol. 2016;17:96.
- 6. Noor S, Ismail M, Ali Z. Potential drug-drug interactions
among pneumonia patients: do these matter in clinical
perspectives? BMC Pharmacol Toxicol. 2019;20(1):45.
- 7. Hanlon JT, Perera S, Newman AB, Thorpe JM, Donohue JM,
Simonsick EM, Shorr RI, Bauer DC, Marcum ZA; Health ABC
Study. Potential drug-drug and drug-disease interactions in
well-functioning community-dwelling older adults. J Clin
Pharm Ther. 2017;42(2):228-233.
- 8. Fadare JO, Ajayi AE, Adeoti AO, Desalu OO, Obimakinde
AM, Agboola SM. Potential drug‑drug interactions among
elderly patients on anti‑hypertensive medications in two
tertiary healthcare facilities in Ekiti State, South‑West Nigeria.
Sahel Med J. 2016;19:32-37.
- 9. Mistry M, Gor A, Ganguly B. Potential drug-drug interactions
among prescribed drugs in paediatric outpatients department
of a tertiary care teaching hospital. J Young Pharm. 2017;9(3):
371.
- 10. Moura C, Acurcio F, Belo N. Drug-drug interactions
associated with length of stay and cost of hospitalization.
Pharm Pharmaceut Sci. 2009; 12(3): 266-272.
- 11. Korucu FC, Senyigit E, Kostek O, Demircan NC, Bulent
Erdogan B, Uzunoglu S, Cicin İ. A retrospective study on
potential drug interactions: A single center experience. Journal
of Oncological Sciences. 2018; 4: 80e84.
- 12. Goren Z, Demirkapu MJ, Acet GA, Cali S, Idrizoglu MG.
Potential drug-drug interactions among prescriptions for
elderly patients in primary health care. Turk J Med Sci. 2017;
47: 47-54.
- 13. Fermini B, Bell DC. On the perspective of an aging population
and its potential impact on drug attrition and pre-clinical
cardiovascular safety assessment. J Pharmacol Toxicol.
Methods 2022;117:107184.
- 14. Al-Musawe L, Torre C, Guerreiro JP, Rodrigues AT, Raposo
JF, Mota-Filipe H, Martins AP. Polypharmacy, potentially
serious clinically relevant drug-drug interactions, and
inappropriate medicines in elderly people with type 2 diabetes
and their impact on quality of life. Pharmacol Res Perspect.
2020;8(4):e00621.
- 15. Abolhassani N, Castioni J, Marques-Vidal P, Vollenweider P,
Waeber G. Determinants of change in polypharmacy status in
Switzerland: the population based CoLaus study. Eur J Clin
Pharmacol. 2017;73:1187-94.
- 16. UpToDate, Inc. Lexi-Interact Online. https://www.uptodate.
com/drug-interactions/#di-druglist, 2020.
- 17. Carpenter M, Berry H, Pelletier AL. Clinically relevant
drug-drug interactions in primary care. Am Fam Physician.
2019;99(9):558-564.
- 18. Oshikoya KA, Oreagba IA, Godman B, Oguntayo FS, Fadare
J, Orubu S, Massele A, Senbanjo IO. Potential drug-drug
interactions in paediatric outpatient prescriptions in Nigeria
and implications for the future. Expert Rev Clin Pharmacol.
2016;9(11):1505-1515.
- 19. Shetty V, Chowta MN, Chowta K N, Shenoy A, Kamath A,
Kamath P. Evaluation of potential drug-drug interactions with
medications prescribed to geriatric patients in a tertiary care
hospital. J Aging Res. 2018;2018:5728957.
- 20. Onyedikachi EA, Ogochukwu AM, Chinwendu AK.
Evaluation of drug-drug interactions among chronic kidney
disease patients of nephrology unit in the University of
Nigeria Teaching Hospital, Ituku-Ozalla, Enugu State. J Basic
Clin Pharma. 2017; 8: S049-S053.
- 21. Adibe MO, Ewelum PC, Amorha KC. Evaluation of drug-drug
interactions among patients with chronic kidney disease in a
South-Eastern Nigeria tertiary hospital: A retrospective study.
Pan Afr Med J. 2017;28:199.
- 22. Marquito AB, da Silva Fernandes NM, Colugnati FAB, de
Paula RB. Identifying potential drug interactions in chronic
kidney disease patients. J Bras Nefrol. 2014; 36(1): 26-34.
- 23. de Araújo MF, dos Santos Alves Pde J, Veras VS, de Araújo TM,
Zanetti ML, Damasceno MM. Drug interactions in Brazilian
type 2 diabetes patients. Int J Nurs Pract. 2013;19(4):423-430.
- 24. Mibielli P, Rozenfeld S, Matos GC, Acurcio Fde A. Interações
medicamentosas potenciais entre idosos em uso dos antihipertensivos
da Relação Nacional de Medicamentos
Essenciais do Ministério da Saúde do Brasil [Potential drugdrug
interactions among elderly using antihypertensives from
the Brazilian List of Essential Medicines]. Cad Saude Publica.
2014;30(9):1947-56.
- 25. Doubova Dubova SV, Reyes-Morales H, Torres-Arreola Ldel
P, Suárez-Ortega M. Potential drug-drug and drug-disease
interactions in prescriptions for ambulatory patients over 50
years of age in family medicine clinics in Mexico City. BMC
Health Serv Res. 2007;7:147.
- 26. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What
is polypharmacy? A systematic review of definitions. BMC
Geriatr. 2017;17(1):230.
- 27. Olsen RM, Sletvold H. Potential drug-to-drug interactions: A
cross sectional study among older patients discharged from
hospital to home care. Saf Health. 2018; 4(1):8.
- 28. Johnell K, Klarin I. The relationship between number of drugs
and potential drug-drug interactions in the elderly: a study
of over 600,000 elderly patients from the Swedish Prescribed
Drug Register. Drug Saf. 2007;30(10):911-8.
- 29. Navaratinaraja TS, Kumanan T, Siraj S, Sreeharan N. Potential
drug-drug interactions among hospitalised elderly patients
in Northern Sri Lanka, a lower middle-income country:
A retrospective analysis. Drugs Real World Outcomes.
2023;10(1):83-95.